Lupus erythematosus
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
Dealraíonn sé mar éiritime beagán corcra.
An gríos féileacán a bhíonn le feiceáil go hiondúil ar an duine.
References
Cruthaíonn sainaithint agus aicmiú cutaneous lupus erythematosus (CLE) dúshláin dhiagnóiseacha, á idirdhealú ó systemic lupus erythematosus le rannpháirtíocht an chraiceann. Tugann staidéir a rinneadh le déanaí solas ar fhachtóirí géiniteacha, comhshaoil agus imdhíoneolaíocha is bun le CLE. Tháinig ionduchtú drugaí chun cinn go sonrach mar cheann de na truicearaitheoirí is tábhachtaí do CLE. Baineann cóireáil le teiripí tráthúla agus sistéamacha, lena n-áirítear bitheolaíochta geallta (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , le héifeachtúlacht léirithe i dtrialacha cliniciúla.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Clúdaíonn Cutaneous lupus erythematosus (CLE) saincheisteanna craicinn éagsúla, a bhféadfadh baint a bheith ag cuid acu le fadhbanna sláinte níos leithne. Déantar é a chatagóiriú i gcineálacha éagsúla, mar shampla acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . Cuimsíonn CCLE discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Is grúpa galair uath-imdhíonachta é Lupus erythematosus ar féidir leo dul i bhfeidhm ar chodanna éagsúla den chorp. Bíonn tionchar ag cineálacha áirithe, amhail systemic lupus erythematosus (SLE) , ar ilorgánaigh, agus bíonn tionchar ag cineálacha eile, mar cutaneous lupus erythematosus (CLE) , ar an gcraiceann. Déanaimid cineálacha éagsúla CLE a chatagóiriú bunaithe ar mheascán de chomharthaí cliniciúla, scrúdú fíocháin, agus tástálacha fola, ach tá go leor éagsúlachta idir daoine aonair. Is minic a fhorbraíonn fadhbanna craicinn de bharr fachtóirí cosúil le nochtadh do sholas na gréine, caitheamh tobac, nó cógais áirithe.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Níl an chúis lupus erythematosus soiléir. I measc cúpla comhionann, má chuirtear isteach ar cheann amháin tá seans 24% go mbeidh an ceann eile chomh maith. Creidtear freisin go n-ardóidh hormóin ghnéis baineann, solas na gréine, caitheamh tobac, easnamh vitimín D, agus ionfhabhtuithe áirithe an riosca.
D’fhéadfadh NSAIDanna, corticosteroidí, imdhíon-bhrúnna, hydroxychloroquine, agus methotrexate a bheith i measc na gcóireálacha. Cé go bhfuil corticosteroids éifeachtach, tá fo-iarsmaí mar thoradh ar úsáid fadtéarmach.